These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36267693)

  • 1. Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies.
    Papadimitriou-Olivgeris M; Cipriano A; Guggisberg N; Kroemer M; Tschopp J; Manuel O; Golshayan D
    Transpl Int; 2022; 35():10721. PubMed ID: 36267693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of SARS-CoV-2 infection among lung transplant recipients: A single center retrospective study.
    Casutt A; Papadimitriou-Olivgeris M; Ioakeim F; Aubert JD; Manuel O; Koutsokera A
    Transpl Infect Dis; 2023 Feb; 25(1):e14007. PubMed ID: 36602439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
    Wang AX; Busque S; Kuo J; Singh U; Röeltgen K; Pinsky BA; Chertow GM; Scandling JD; Lenihan CR
    Kidney360; 2022 Jan; 3(1):133-143. PubMed ID: 35368573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
    Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
    Elife; 2022 Nov; 11():. PubMed ID: 36413383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.
    Yetmar ZA; Bhaimia E; Bierle DM; Ganesh R; Razonable RR
    Transpl Infect Dis; 2022 Apr; 24(2):e13779. PubMed ID: 34932874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes.
    Wong G; Rowlandson M; Sabanayagam D; Ginn AN; Kable K; Sciberras F; Au E; Draper J; Arnott A; Sintchenko V; Dwyer DE; Chen SCA; Kok J
    Transplantation; 2022 Sep; 106(9):1860-1866. PubMed ID: 35675438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?
    Romero A; Laurent C; Lebourg L; Lemée V; Hanoy M; Le Roy F; Grange S; Lemoine M; Guerrot D; Bertrand D
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543747
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
    Kip KE; McCreary EK; Collins K; Minnier TE; Snyder GM; Garrard W; McKibben JC; Yealy DM; Seymour CW; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
    Ann Intern Med; 2023 Apr; 176(4):496-504. PubMed ID: 37011399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients.
    Sarrell BA; Bloch K; El Chediak A; Kumm K; Tracy K; Forbes RC; Langone A; Thomas L; Schlendorf K; Trindade AJ; Perri R; Wright P; Concepcion BP
    Transpl Infect Dis; 2022 Feb; 24(1):e13759. PubMed ID: 34787345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
    Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
    Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients.
    Bachmann F; Budde K; Suttorp N; Lingscheid T; Stegemann MS; Osmanodja B; Schrezenmeier E; Duettmann W; Weber U; Naik M; Lehner LJ; Kahl A; Duerr M; Eckardt KU; Waiser J; Choi M; Halleck F
    Transpl Int; 2022; 35():10109. PubMed ID: 35431640
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients.
    Crane C; Phebus E; Ingulli E
    Pediatr Nephrol; 2022 Feb; 37(2):449-453. PubMed ID: 34522992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
    Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
    Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients.
    Bertrand D; Laurent C; Lemée V; Lebourg L; Hanoy M; Le Roy F; Nezam D; Pruteanu D; Grange S; de Nattes T; Lemoine M; Candon S; Guerrot D
    Kidney Int; 2022 Aug; 102(2):440-442. PubMed ID: 35618097
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series.
    Fernandes G; Devresse A; Scohy A; De Greef J; Yombi JC; Belkhir L; Darius T; Mourad M; Buemi A; Kabamba B; Goffin E; Kanaan N
    Kidney Med; 2022 Jun; 4(6):100470. PubMed ID: 35493029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves.
    Zeitler K; Piccicacco N; O'Neal M; Montero J; Myers A; Strebig D; Nestler S; Anger LB; Kim K
    Transpl Infect Dis; 2023 Aug; 25(4):e14095. PubMed ID: 37378536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities.
    Klein EJ; Hardesty A; Vieira K; Farmakiotis D
    Am J Transplant; 2022 Feb; 22(2):640-645. PubMed ID: 34591350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Agrawal P; Damania D; Cseh A; Grab J; Strom L; Frank B; Patel D; Clyatt G
    Vaccine; 2023 Aug; 41(35):5195-5200. PubMed ID: 37451874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.